H Conjeevaram's research while affiliated with The National Institute of Diabetes and Digestive and Kidney Diseases and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (5)
Therapy with ribavirin for 6-12 months is associated with decreases in serum aminotransferases in some patients with chronic hepatitis C. We have assessed the practicality and safety of prolonged therapy with ribavirin. Six patients with chronic hepatitis C were given 1000-1200 mg of ribavirin daily for 24 months. Serum aminotransferases and hepati...
Citations
... However, clinical experience with the use of methotrexate in the treatment of PBC is becoming substantial. [13][14][15][16][17][18][19][20] A large, rigorously conducted, multicenter, randomized, placebo-controlled trial of a combination of methotrexate and UDCA in patients with PBC has been underway in the United States for several years. 21 The definitive results of this important trial are awaited. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/277050955976704-1443065503873_Q64/Richard-Sallie.jpg)
... These data are consistent with those observed in postmenopausal osteoporosis, 37 but are in disagreement with those reported in patients with PBC. Actually, the VDR polymorphism has been proposed as a predictor of bone loss, 42 and a significant predictor of decreased BMD in patients with PBC. 43 In this latter study, patients homozygous for the b allele had lower spine BMD than those who were heterozygous or homozygous for the B allele, which is the allele commonly associated with low bone mass in most studies. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/273808888168449-1442292534218_Q64/David-Herion-2.jpg)
... Ribavirin had been explored for the treatment of HCV contamination in the mid 1990s. Notwithstanding perceptions of upgrades in serum aminotransferase levels [6] and hepatic histology [7], ribavirin had no huge impact on HCV RNA levels when utilized as a solitary operator. As respects virology freedom, drawing out the course of treatment didn't give any profit (Hoofnagle et al., 1996). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272470401875986-1441973414380_Q64/Daryl-Lau.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/311016951353345-1451163627555_Q64/Adrian-Di-Bisceglie.jpg)
